3-Methoxyeticyclidine (3-MeO-PCE) is a dissociative of the arylcyclohexylamine class and the N-ethyl analog of 3-MeO-PCP — a single carbon atom distinguishing the two compounds but producing meaningfully different experiences. Where 3-MeO-PCP is often described as cold, analytical, and almost clinical in its dissociation, 3-MeO-PCE is warmer, more euphoric, more stimulating, and considerably more dangerous because of it. The euphoria makes it compulsively redosable in a way that 3-MeO-PCP typically is not, and the stimulation means you feel functional enough to keep going when you should have stopped hours ago. Community reports of manic episodes, psychotic breaks, and multi-day binges are not rare — they are a defining feature of the compound's reputation.
Pharmacologically, 3-MeO-PCE is a potent NMDA receptor antagonist (Ki = 61 nM) with significant serotonin transporter affinity (Ki = 115 nM) and moderate dopamine transporter binding (Ki = 743 nM). That serotonin activity is unusually high for a dissociative and likely accounts for the compound's distinctly mood-elevating, almost empathogenic warmth at lower doses. The dopamine affinity fuels the stimulation and the reinforcing properties that make compulsive use a real concern. Additional binding at sigma-2 receptors (Ki = 525 nM), alpha-2A adrenergic receptors (Ki = 964 nM), and histamine H2 receptors (Ki = 2097 nM) rounds out a pharmacological profile that is substantially broader than ketamine's relatively clean NMDA antagonism.
The experience spans 8 to 12 hours — closer to 3-MeO-PCP territory than the 2-hour window of ketamine — and the tail end is notorious. Stimulation often outlasts the dissociative depth by several hours, leaving users wired and awake long after they thought they were done. It is during this extended offset that mania, delusions of sobriety, and psychotic symptoms most commonly emerge. Reddit and Bluelight are full of accounts that follow the same arc: euphoric come-up, brilliant-feeling peak, then a slow slide into grandiose thinking and poor decisions that the user does not recognize as impaired until the next day.
3-MeO-PCE emerged in the research chemical market in the mid-2010s, identified alongside 3-MeO-PCP and 4-MeO-PCP in a 2012 UK Advisory Council on the Misuse of Drugs report that characterized the binding profiles of several novel arylcyclohexylamines. It was swept into UK Class B scheduling under a broad arylcyclohexylamine generic clause in February 2013 and is controlled in Germany, Switzerland, and Turkey. In unregulated markets it remains available, though its reputation for psychiatric adverse effects has kept it a niche compound compared to more forgiving dissociatives.
Safety at a Glance
High Risk- Use Volumetric Dosing — Non-Negotiable
- Respect the Mania Risk — This Is Not Like Ketamine
- Toxicity: Formal Toxicity Data No systematic toxicological studies of 3-MeO-PCE in humans or animals have been published. The e...
- Dangerous with: Acetylfentanyl, Buprenorphine, Codeine, Desomorphine (+15 more)
- Overdose risk: Recognizing an Overdose The primary overdose risk with 3-MeO-PCE is psychiatric, not respiratory ...
If someone is in crisis, call 911 or Poison Control: 1-800-222-1222
Dosage
insufflated
oral
Duration
insufflated
Total: 3 hrs – 5 hrsoral
Total: 4 hrs – 8 hrsHow It Feels
The first indication is a gathering brightness behind the eyes, a sense that someone has slowly turned up the gain on consciousness itself. Fifteen to twenty minutes in, a clean stimulation begins to build — not the jittery push of amphetamines but something more architectural, as though the scaffolding of your mind is being reinforced and extended upward. Your thoughts accelerate, not chaotically but with purpose, each one arriving fully formed and seeming to connect to the next with an almost musical logic. The body feels light, alert, ready for motion.
The come-up can last an hour or more, and during this time the dissociation and the stimulation climb together in lockstep. Sound becomes crisp and layered — you hear the room itself, its dimensions and surfaces, as though your ears have developed a form of sonar. Vision takes on a high-definition quality; colors sharpen, edges clarify, and there is a faint luminosity to ordinary objects, as though everything is lit from within. The body high is energetic and clean, a sense of physical capability that makes walking, stretching, even dancing feel fluid and natural. There is no numbness here, or very little — instead, a heightened awareness of your own physicality.
The peak is where the compound reveals its manic potential. Thoughts do not merely flow — they cascade, each one spawning three more, and there is a growing conviction that you are perceiving reality at a level of resolution that is normally unavailable. Conversations become electric; words arrive with uncanny precision, and you feel capable of articulating ideas that have eluded you for years. This cognitive acceleration is exhilarating, but it has a shadow: the line between insight and delusion begins to blur, and the certainty that accompanies each thought can become a trap if you are not careful. The emotional tone is bright and expansive, occasionally tipping into grandiosity. There is warmth here too — a serotonergic glow that makes people and music and textures feel meaningful in a way that recalls a very mild empathogen more than a typical dissociative.
The duration is formidable — eight, ten, sometimes twelve hours from ingestion to baseline. The descent is gradual, the stimulation persisting long after the dissociative depth has ebbed. Sleep may not come for many hours after you consider yourself sober. The afterglow carries a residual mental sharpness and a vague sense of accomplishment, as though you have completed some demanding cognitive task. But there is also, sometimes, a faint unease — the echo of thoughts that felt true at the time and now, in daylight, seem less certain. This is the compound's warning label written in experiential terms: what felt like brilliance at 2 AM may look like mania by morning.
Subjective Effects
The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.
Physical Effects
Physical(21)
- Appetite suppression— A distinct decrease in hunger and desire to eat, ranging from reduced interest in food to complete d...
- Bodily control enhancement— Bodily control enhancement is the subjective feeling of improved physical precision, coordination, a...
- Changes in felt gravity— A distortion of one's proprioceptive sense of gravity in which the perceived direction of gravitatio...
- Dehydration— A state of insufficient bodily hydration manifesting as persistent thirst, dry mouth, and physical d...
- Difficulty urinating— Difficulty urinating, also known as urinary retention, is the experience of being unable to easily p...
- Dizziness— A sensation of spinning, swaying, or lightheadedness that impairs balance and spatial orientation, o...
- Increased blood pressure— Increased blood pressure (hypertension) is an elevation of arterial pressure above the normal 120/80...
- Increased heart rate— A noticeable acceleration of heartbeat that can range from a subtle awareness of one's pulse to a fo...
- Motor control loss— A distinct decrease in the ability to control one's physical body with precision, balance, and coord...
- Nausea— An uncomfortable sensation of queasiness and stomach discomfort that may or may not lead to vomiting...
- Nausea suppression— Nausea suppression is the pharmacological reduction or elimination of nausea and the urge to vomit, ...
- Pain relief— A suppression of negative physical sensations such as aches and pains, ranging from dulled awareness...
- Perception of bodily lightness— Perception of bodily lightness is the subjective feeling that one's body has become dramatically lig...
- Physical autonomy— Physical autonomy is the experience of one's body performing actions — from simple tasks like walkin...
- Physical euphoria— An intensely pleasurable bodily sensation that can manifest as waves of warmth, tingling electricity...
- Respiratory depression— A dangerous slowing and shallowing of breathing that can progress from barely noticeable reductions ...
- Restless legs— Restless legs is an uncomfortable neurological effect characterized by an irresistible compulsion to...
- Sedation— A state of deep physical and mental calming that manifests as a progressive desire to remain still, ...
- Seizure— Uncontrolled brain electrical activity causing convulsions and loss of consciousness -- a life-threa...
- Spatial disorientation— Spatial disorientation is the inability to accurately perceive one's position or orientation within ...
- Stimulation— A state of heightened physical and mental energy characterized by increased wakefulness, elevated mo...
Tactile(2)
- Tactile enhancement— The sense of touch becomes dramatically heightened, making physical contact feel intensely pleasurab...
- Tactile suppression— A progressive decrease in the ability to feel physical touch, ranging from mild numbness to complete...
Cognitive & Perceptual Effects
Visual(12)
- Colour enhancement— An intensification of the brightness, vividness, and saturation of colors in the external environmen...
- Double vision— The visual experience of seeing a single object as two separate, overlapping images, similar to cros...
- Environmental cubism— A visual distortion in which the environment and objects within it appear fragmented into geometric,...
- Frame rate suppression— Perception of visual motion as choppy discrete frames rather than smooth continuous flow, resembling...
- Geometry— The experience of perceiving complex, ever-shifting geometric patterns superimposed over the visual ...
- Internal hallucination— Vivid, detailed visual experiences perceived within an imagined mental landscape that can only be se...
- Perspective distortions— Distortion of perceived depth, distance, and size of real objects, making things appear closer, furt...
- Perspective hallucination— A hallucinatory phenomenon in which the observer's visual perspective shifts from the normal first-p...
- Scenery slicing— The visual field fractures into distinct, cleanly cut sections that slowly drift apart from their or...
- Settings, sceneries, and landscapes— The perceived environment in which hallucinatory experiences take place, ranging from recognizable l...
- Visual acuity suppression— Vision becomes blurred, indistinct, and out of focus, as though looking through a smudged lens. Fine...
- Visual disconnection— A dissociative visual effect involving a progressive detachment from visual perception, ranging from...
Cognitive(22)
- Amnesia— A complete or partial inability to form new memories or recall existing ones during and after substa...
- Analysis suppression— Analysis suppression is a cognitive impairment in which the capacity for logical reasoning, critical...
- Anxiety— Intense feelings of apprehension, worry, and dread that can range from a subtle background unease to...
- Anxiety suppression— A partial to complete suppression of anxiety and general unease, producing a calm, relaxed mental st...
- Cognitive euphoria— A cognitive and emotional state of intense well-being, elation, happiness, and joy that manifests as...
- Compulsive redosing— An overwhelming, difficult-to-resist urge to continuously take more of a substance in order to maint...
- Conceptual thinking— A shift in the nature of thought from verbal, linear sentence structures to intuitive, non-linguisti...
- Creativity enhancement— An increase in the ability to imagine new ideas, overcome creative blocks, think about existing conc...
- Deja vu— Intense, often prolonged sensation of having already experienced the current moment, common with psy...
- Delirium— Delirium is a serious and potentially dangerous state of acute mental confusion involving disorienta...
- Delusion— A delusion is a fixed, false belief that is held with unshakeable certainty and is impervious to con...
- Depersonalization— A detachment from one's own sense of self, body, or mental processes, as if observing oneself from o...
- Depression— A persistent state of low mood, emotional numbness, hopelessness, and diminished interest or pleasur...
- Derealization— A perceptual disturbance in which the external world feels profoundly unreal, dreamlike, or artifici...
- Disinhibition— A marked reduction in social inhibitions, self-consciousness, and behavioral restraint that manifest...
- Immersion enhancement— A heightened capacity to become fully absorbed and engrossed in external media such as music, films,...
- Introspection— An enhanced state of self-reflective awareness in which one feels drawn to examine their own thought...
- Mania— Abnormally elevated mood, energy, and activity with impulsive behavior and grandiosity, associated w...
- Memory suppression— A dose-dependent inhibition of one's ability to access and utilize short-term and long-term memory, ...
- Psychosis— Psychosis is a serious psychiatric state involving a fundamental break from consensus reality — char...
- Thought deceleration— The experience of thoughts occurring at a markedly reduced pace, as if the mind has been placed into...
- Time distortion— Subjective perception of time becomes dramatically altered — minutes may feel like hours, or hours p...
Multi-sensory(3)
- Olfactory hallucination— Olfactory hallucinations (phantosmia) involve the perception of convincing phantom smells — pleasant...
- Scenarios and plots— Scenarios and plots are the narrative structures that emerge within hallucinatory states — coherent ...
- Synaesthesia— Stimulation of one sense triggers involuntary experiences in another — seeing sounds as colors, tast...
Transpersonal(2)
- Ego death— A profound dissolution of the sense of self in which personal identity, memories, and the boundary b...
- Unity and interconnectedness— A profound sense that identity extends beyond the self to encompass other people, nature, or all of ...
Pharmacology
NMDA Receptor Antagonism
3-MeO-PCE's primary mechanism is non-competitive antagonism of the NMDA receptor, with a binding affinity of Ki = 61 nM — placing it in the same potency range as 3-MeO-PCP (Ki = 20 nM) and substantially more potent than ketamine (Ki ≈ 659 nM at the PCP binding site). Like all arylcyclohexylamine dissociatives, it blocks the open NMDA channel in a use-dependent manner, disrupting glutamatergic signaling across cortical and thalamocortical circuits. The resulting disruption of sensory gating produces the characteristic dissociative syndrome: progressive uncoupling of sensory processing from conscious awareness, analgesia, and at sufficient doses, complete dissociative anesthesia.
Serotonin Transporter Affinity
What distinguishes 3-MeO-PCE from most arylcyclohexylamine dissociatives is its notable affinity for the serotonin transporter (SERT, Ki = 115 nM). This is a remarkably potent interaction for a dissociative — for context, MDMA's SERT affinity is in the low micromolar range. Serotonin reuptake inhibition at this level likely contributes to the compound's distinctly warm, mood-elevating, and occasionally empathogenic quality at lower doses. It may also explain why 3-MeO-PCE feels subjectively different from 3-MeO-PCP despite their structural similarity: the serotonergic component adds an emotional richness that 3-MeO-PCP's more dopamine-weighted profile lacks.
Dopamine and Stimulant Properties
Moderate dopamine transporter binding (Ki = 743 nM) contributes to 3-MeO-PCE's pronounced stimulating character. This is less potent than 3-MeO-PCP's dopamine affinity but sufficient to produce the clean, focused stimulation that users consistently report. The dopaminergic activity is also a key driver of the compound's reinforcing properties and its association with compulsive redosing — the euphoria feels rewarding in a way that purely NMDA-mediated dissociation does not.
Additional Receptor Targets
3-MeO-PCE shows binding at several additional sites: sigma-2 receptors (Ki = 525 nM), alpha-2A adrenergic receptors (Ki = 964 nM), histamine H2 receptors (Ki = 2097 nM), and sigma-1 receptors (Ki = 4519 nM). The sigma-2 binding may contribute to hallucinogenic properties. Alpha-2A adrenergic antagonism could partly explain the cardiovascular stimulation (elevated heart rate and blood pressure) reported at higher doses.
Comparison to 3-MeO-PCP
The N-ethyl versus N-methyl (actually N-propyl in the piperidine ring) structural difference produces meaningful pharmacological divergence. 3-MeO-PCP is more potent at the NMDA receptor and shows stronger dopaminergic activity, but 3-MeO-PCE's serotonergic profile adds warmth and euphoria that 3-MeO-PCP lacks. Community experience is consistent: the two converge at high doses when NMDA antagonism dominates, but at low to moderate doses they feel qualitatively distinct. The practical consequence is that 3-MeO-PCE's greater euphoria creates a stronger pull toward redosing, while 3-MeO-PCP's colder, more analytical character is somewhat self-limiting.
Pharmacokinetics
Onset is typically 15-30 minutes oral, faster insufflated. Duration is long: 4-6 hours of primary effects with residual stimulation extending to 8-12 hours total. The extended tail of stimulation outlasting dissociation is pharmacokinetically significant — it suggests that the NMDA-blocking effects clear faster than the monoamine reuptake inhibition, leaving users stimulated and disinhibited without the protective "obviously intoxicated" feeling of active dissociation.
Detection Methods
Standard Drug Panel Inclusion
3-MeO-PCE is unlikely to reliably trigger a positive result on standard PCP immunoassay screens. While it retains the arylcyclohexylamine core, the combination of the methoxy group and ethyl nitrogen substitution reduces cross-reactivity with PCP-targeted antibodies. Some immunoassay platforms may produce weak or borderline positive results, but detection cannot be relied upon. Standard drug panels will typically return negative results.
Urine Detection
3-MeO-PCE is detectable in urine for approximately 3 to 7 days after a single dose. The compound is metabolized by O-demethylation to 3-HO-PCE and by further hydroxylation. Both the parent compound and the O-demethylated metabolite are present in urine. Detection requires LC-MS/MS methods specifically including 3-MeO-PCE and 3-HO-PCE in the analytical panel. The lipophilic arylcyclohexylamine structure promotes tissue accumulation and extended urinary detection.
Blood and Serum Detection
Blood detection windows are 1 to 3 days. Pharmacokinetic data comes primarily from case reports. Active blood concentrations are in the low to moderate nanogram-per-milliliter range. The compound's relatively long duration of action (4 to 6 hours) suggests moderate metabolic stability.
Hair Follicle Detection
Hair analysis for 3-MeO-PCE is feasible using LC-MS/MS methods, with expected detection windows up to 90 days. The basic, lipophilic nature of the compound favors hair incorporation.
Confirmatory Methods
LC-MS/MS is the preferred confirmatory method. Both 3-MeO-PCE and its O-demethylated metabolite 3-HO-PCE should be included in the analytical panel. GC-MS can also confirm the compound with appropriate reference standards.
Reagent Testing
The Marquis reagent produces no reaction or a very faint yellow color. The Mandelin reagent may produce an orange to brown color. The Mecke reagent may produce a green to brown reaction. These reagent profiles are insufficient for definitive identification among arylcyclohexylamine analogues.
Interactions
| Substance | Status | Note |
|---|---|---|
| Acetylfentanyl | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Buprenorphine | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Codeine | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Desomorphine | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Dextropropoxyphene | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Dihydrocodeine | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Ethylmorphine | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Fentanyl | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Heroin | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Hydrocodone | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Hydromorphone | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Kratom | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Methadone | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Morphine | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Naloxone | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| O-Desmethyltramadol | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Oxycodone | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Oxymorphone | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Pethidine | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| 1,4-Butanediol | Caution | Both cause CNS depression; increased risk of vomiting, unconsciousness, and respiratory depression |
| 2-Fluorodeschloroketamine | Caution | Compounding dissociative effects can cause confusion, mania, and loss of motor control |
| 2M2B | Caution | Both cause CNS depression; increased risk of vomiting, unconsciousness, and respiratory depression |
| 3-Cl-PCP | Caution | Compounding dissociative effects can cause confusion, mania, and loss of motor control |
| 3-HO-PCE | Caution | Compounding dissociative effects can cause confusion, mania, and loss of motor control |
| 1,3-Butanediol | Low Risk & Synergy | Produces unique synergistic effects; often combined |
| 1B-LSD | Low Risk & Synergy | Produces unique synergistic effects; often combined |
| 1cP-AL-LAD | Low Risk & Synergy | Produces unique synergistic effects; often combined |
| 1cP-LSD | Low Risk & Synergy | Produces unique synergistic effects; often combined |
| 1cP-MiPLA | Low Risk & Synergy | Produces unique synergistic effects; often combined |
History
Origins in Arylcyclohexylamine Chemistry
3-MeO-PCE's structural lineage traces back to the systematic modification of phencyclidine (PCP) analogs that began in the 1950s and 1960s. PCP was synthesized by Parke-Davis in 1956 as a surgical anesthetic. Its severe emergence reactions led to the development of ketamine (1962), which proved far more manageable clinically. Eticyclidine (PCE), the N-ethyl analog of PCP, was also explored during this period but never reached clinical use — it was more potent and longer-acting than PCP with no clear therapeutic advantage. 3-MeO-PCE is the 3-methoxy-substituted derivative of PCE: the same ethyl nitrogen chain, with a methoxy group added to the phenyl ring.
Research Chemical Emergence
3-MeO-PCE appeared in online research chemical markets in the early to mid-2010s, part of a wave of novel arylcyclohexylamines that included 3-MeO-PCP, methoxetamine (MXE), deschloroketamine (DCK), and O-PCE. Its binding profile was formally characterized in a 2012 report by the UK Advisory Council on the Misuse of Drugs (ACMD), which examined 3-MeO-PCE alongside 3-MeO-PCP and 4-MeO-PCP as part of an investigation into methoxetamine and structurally related compounds. This report established the Ki values (61 nM NMDA, 115 nM SERT, 743 nM DAT) that remain the primary pharmacological reference data for the compound. The findings were subsequently published in greater detail in peer-reviewed literature.
UK Scheduling and Regulatory Response
On February 26, 2013, 3-MeO-PCE became a Class B controlled substance in the United Kingdom under a broad arylcyclohexylamine generic clause added to the Misuse of Drugs Act via Statutory Instrument 2013/239. This clause was specifically designed to capture both existing and future arylcyclohexylamine analogs, reflecting the ACMD's concern about the proliferation of novel dissociative compounds on the research chemical market.
Community Documentation
Unlike earlier generations of dissociatives, 3-MeO-PCE's user knowledge base was built almost entirely through online community documentation — Bluelight trip reports, Reddit experience accounts, and PsychonautWiki entries compiled by volunteer contributors. This decentralized harm reduction research established the compound's reputation for manic and psychotic adverse events, providing warnings that no formal clinical literature existed to offer. The community consensus — that 3-MeO-PCE is meaningfully more psychiatrically dangerous than structurally similar compounds like 3-MeO-PCP or MXE — emerged from hundreds of individual reports and has remained consistent.
Harm Reduction
Use Volumetric Dosing — Non-Negotiable
3-MeO-PCE is active at doses where standard milligram scales (the typical 0.001g models) cannot provide reliable accuracy. A 5 mg error at the 15-25 mg dose range represents a 20-33% deviation that can mean the difference between a manageable experience and a manic episode. Dissolve a known quantity in a measured volume of propylene glycol or distilled water and dose volumetrically. This single precaution prevents more adverse outcomes than any other.
Respect the Mania Risk — This Is Not Like Ketamine
3-MeO-PCE's most dangerous property is not respiratory depression or physical toxicity — it is the psychiatric risk. Mania, psychotic delusions, grandiosity, and dangerous behavior are reported at rates far exceeding other dissociatives. These states typically emerge during the long offset phase, when stimulation persists after dissociative insight has faded. The user feels sober, lucid, and brilliant, and is none of these things. Have a sober sitter who understands this pattern and who has explicit permission to intervene if your behavior becomes erratic.
Never Redose Before Full Sobriety
Compulsive redosing is the single most common pathway to serious adverse events with 3-MeO-PCE. The euphoria and stimulation create a powerful urge to take more, and the long onset means redosing before the first dose has fully manifested is extremely common. Pre-measure your dose, put the remaining material away in a location that requires effort to access, and commit to the rule: one dose per session, no exceptions. Delusions of sobriety — genuinely believing you are baseline when you are profoundly intoxicated — are a well-documented feature of this compound.
Dangerous Combinations
- Stimulants (amphetamines, cocaine, cathinones) — Dramatically amplifies cardiovascular strain and psychiatric risk. 3-MeO-PCE is already stimulating; adding more stimulation is a direct path to hypertensive crisis or psychosis
- Psychedelics — The combination massively escalates the risk of psychotic episodes. The cognitive acceleration of 3-MeO-PCE combined with psychedelic reality distortion can produce terrifying and dangerous states
- Other dissociatives — Unpredictable potentiation. Different receptor profiles stack in ways that are not simply additive
- CNS depressants (alcohol, benzodiazepines, opioids) — Risk of respiratory depression, aspiration, and loss of consciousness
- MAOIs — Potentially dangerous given 3-MeO-PCE's serotonin transporter affinity. Serotonin syndrome risk
Limit Frequency Strictly
Use no more than once every two weeks at absolute maximum. Weekly or more frequent use rapidly escalates tolerance, dependence risk, and the probability of manic or psychotic episodes. Multiple reports describe a progression from occasional use to daily dosing within weeks, driven by the compound's reinforcing euphoria.
Benzodiazepine Safety Net
Keep a benzodiazepine (diazepam 10-20 mg) available as an emergency measure for manic or psychotic symptoms. This is standard dissociative harm reduction but especially important for 3-MeO-PCE given its elevated psychiatric risk profile.
Toxicity & Safety
Formal Toxicity Data
No systematic toxicological studies of 3-MeO-PCE in humans or animals have been published. The exact toxic dose is unknown. All toxicity information derives from case reports, community experience accounts, and extrapolation from structurally related compounds.
Psychiatric Toxicity — The Primary Danger
3-MeO-PCE is reported to cause psychosis, mania, and delusional states at rates significantly higher than other dissociatives including ketamine, MXE, and diphenidine. Online experience reports describe psychotic delirium, amnesia, grandiose delusions, dangerous behavior, and hospitalization. These effects are dose-dependent but can occur even at moderate doses, particularly with repeated use. The mechanism likely involves the compound's combined NMDA antagonism, serotonin reuptake inhibition, and dopaminergic stimulation — a pharmacological cocktail that at sufficient doses destabilizes reality testing, elevates mood to pathological levels, and removes the self-awareness needed to recognize that anything is wrong. The long duration of action (8-12 hours) means these states can persist for extended periods.
Urinary Tract Toxicity
Like all arylcyclohexylamine dissociatives, 3-MeO-PCE likely shares ketamine's potential for bladder and urinary tract damage with chronic heavy use. However, because 3-MeO-PCE is far more potent by weight than ketamine (active at 10-25 mg versus ketamine's 50-300 mg), the absolute amount of material passing through the urinary tract per dose is substantially lower. This means uropathy risk is likely reduced compared to equivalent-frequency ketamine use, but not eliminated — particularly with the dose escalation that accompanies tolerance development. Symptoms of concern include urinary frequency, urgency, pelvic pain, and blood in urine.
Cardiovascular Stress
Elevated heart rate and blood pressure are reported at moderate to high doses, consistent with the compound's dopaminergic and adrenergic activity. Chronic use adds cumulative cardiovascular strain. The combination of stimulation and dissociation means users may not notice cardiovascular distress symptoms that would otherwise prompt them to stop.
Dangerous Interactions
- CNS depressants increase respiratory depression and aspiration risk
- Stimulants compound cardiovascular stress and dramatically amplify psychosis risk
- Psychedelics potentiate psychiatric destabilization unpredictably
- MAOIs risk serotonin syndrome given 3-MeO-PCE's significant SERT affinity
- Other dissociatives produce unpredictable potentiation across multiple receptor systems
Neurotoxicity
Olney's lesions (vacuolization of neurons in the posterior cingulate and retrosplenial cortex) have been observed in rodents following administration of NMDA antagonists. Whether this translates to human neurotoxicity at recreational doses of arylcyclohexylamines remains unresolved. Chronic heavy use of 3-MeO-PCE should be assumed to carry neurotoxic risk until evidence demonstrates otherwise.
Addiction Potential
Highly addictive with a pronounced tendency toward compulsive use patterns. Among dissociatives, 3-MeO-PCE is consistently reported by community experience as more habit-forming than ketamine, MXE, diphenidine, or ephenidine. The reinforcement mechanism is multifaceted: dopaminergic stimulation provides direct reward, serotonergic mood elevation creates emotional appeal, the cognitive acceleration feels genuinely useful and productive, and the euphoria makes the experience intrinsically desirable in a way that more neutral dissociatives are not. Compulsive redosing within a single session is common and can escalate to daily use remarkably quickly. Multiple online accounts describe a progression from exploratory use to daily dosing within weeks, driven by the compound's unique combination of accessible euphoria and an intellectual grandiosity that makes the user feel like the best version of themselves. Tolerance develops with prolonged and repeated use, requiring escalating doses that further increase psychiatric risk. Psychological dependence can be intense, with cravings, dysphoria, and motivational deficits upon cessation. Physical withdrawal is less characterized but likely includes insomnia, anxiety, and cognitive fog consistent with other dissociative withdrawal syndromes. The most insidious aspect is that the mania and grandiosity produced by 3-MeO-PCE can themselves mask the recognition of problematic use — the user feels exceptional, not addicted.
Overdose Information
Recognizing an Overdose
The primary overdose risk with 3-MeO-PCE is psychiatric, not respiratory — though both are possible. Signs that require immediate attention include:
- Manic or psychotic behavior — Grandiose delusions, paranoia, agitation, aggressive or bizarre behavior, loss of contact with reality. This is the most common form of 3-MeO-PCE overdose and can emerge even at doses only modestly above the intended range
- Complete unresponsiveness — Inability to be roused by voice or physical stimulation beyond the expected duration (more than 6-8 hours)
- Seizures — Rare but documented with arylcyclohexylamine overdoses
- Severely elevated heart rate or blood pressure — The stimulant properties mean cardiovascular crisis is a real concern at high doses
- Respiratory depression — Particularly in combination with CNS depressants
- Vomiting while unconscious — Aspiration risk when protective reflexes are suppressed
What To Do
For psychiatric emergencies (mania, psychosis, agitation): move the person to a calm, low-stimulation environment. Speak calmly and avoid confrontation. Administer a benzodiazepine (diazepam 10-20 mg) if available and the person can swallow safely. Call emergency services if the person is a danger to themselves or others, if psychotic symptoms are severe, or if the situation is not improving.
For physical emergencies: place the person in the recovery position to prevent aspiration. Monitor breathing continuously. Call emergency services immediately if breathing is slow, shallow, or irregular, if the person is unresponsive to stimulation, or if seizures occur. Be honest with medical personnel about what was consumed and approximate timing and dose — 3-MeO-PCE is obscure enough that clinicians are unlikely to be familiar with it, so providing the name and noting that it is a potent NMDA antagonist with stimulant properties is genuinely helpful for treatment decisions.
Why 3-MeO-PCE Overdoses Happen
The combination of compulsive redosing urges, delusions of sobriety, and extremely long duration creates a characteristic overdose pattern. Users redose during what they perceive as the come-down, not realizing they are still significantly intoxicated. Each additional dose extends the experience and increases the probability of psychiatric adverse effects. The stimulant component maintains a false sense of lucidity that delays recognition of how impaired the person actually is.
Dangerous Interactions
The combinations listed below may be life-threatening. Independent research should always be conducted to ensure safety when combining substances.
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Tolerance
| Full | with prolonged and repeated use |
| Half | 3 - 7 days |
| Zero | 1 - 2 weeks |
Cross-tolerances
Legal Status
Czech Republic:** 6-APB is a Schedule I (List 4) substance. It may be used for research and restricted therapeutic purposes. (§ 1, d), 1. of Nařízení vlády č. 463/2013 Sb.)
Germany:** 3-MeO-PCE is controlled under the NpSG (New Psychoactive Substances Act) as of July 18, 2019. Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.
Switzerland:** 3-MeO-PCE is a controlled substance specifically named under Verzeichnis E.
Turkey:** 3-MeO-PCE is a classed as drug and is illegal to possess, produce, supply, or import.
United Kingdom** - 3-MeO-PCE is a class B drug in the UK and is illegal to possess, produce, supply, or import. As an N-alkyl derivative of 1-phenylcyclohexylamine substituted in the phenyl ring with an alkoxy substituent, it is covered by the arylcyclohexylamine generic clause added to the Misuse of Drugs Act by S.I. 2013/239, which came into effect on the 26th February 2013.
Responsible use
Research chemical
3-MeO-PCE (Wikipedia)
3-MeO-PCE (Isomer Design)
3-MeO-PCE (Bluelight)
Interview with a Ketamine Chemist (VICE)
Morris, H., & Wallach, J. (2014). From PCP to MXE: A comprehensive review of the non-medical use of dissociative drugs. Drug Testing and Analysis, 6(7–8), 614–632. https://doi.org/10.1002/dta.1620
a
Experience Reports (2)
Tips (8)
Dissociative aftereffects from 3-MeO-PCE can include cognitive fog, poor coordination, and impaired judgment for hours after the main experience. Do not drive, make important decisions, or use machinery until fully baseline.
3-MeO-PCE has significant serotonin transporter activity similar to 3-MeO-PCP. This makes combining it with serotonergic substances (SSRIs, MDMA, MAOIs) potentially dangerous. Treat it with the same interaction precautions as any serotonergic drug.
The mania from 3-MeO-PCE can be useful for motivation at low doses but quickly becomes counterproductive. Do not chase the manic state — it can lead to grandiose thinking, poor decisions, and psychotic episodes at higher doses.
3-MeO-PCE is known for its manic and stimulating qualities among dissociatives. It is excellent for creative activities, yoga, and meditation at low doses due to its unique combination of dissociation and mental energy.
Yoga and meditation on low-dose 3-MeO-PCE is frequently praised in the community. The dissociation allows deeper body awareness and the stimulation keeps you engaged rather than sedated. Start with a threshold dose if combining with physical activity.
3-MeO-PCE pairs interestingly with other dissociatives like O-PCE, but combinations should be done with extreme caution using sub-threshold doses of each. The effects are not simply additive and unexpected potentiation can occur.
Community Discussions (5)
See Also
References (3)
- Ketamine as a rapid antidepressant — Berman et al. Biological Psychiatry (2000)paper
- 3-MeO-PCE - TripSit Factsheet
TripSit factsheet for 3-MeO-PCE
tripsit - 3-MeO-PCE - Wikipedia
Wikipedia article on 3-MeO-PCE
wikipedia